Global Celiac Disease Market to 2030 - Insights, Epidemiology and Market Forecast - ResearchAndMarkets.com

·5-min read

The "Celiac Disease (CD) - Market Insights, Epidemiology and Market Forecast- 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the Celiac Disease (CD), historical and forecasted epidemiology as well as the Celiac Disease (CD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Celiac Disease (CD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Celiac Disease (CD) market size from 2017 to 2030. The report also covers current Celiac Disease (CD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Celiac Disease (CD) - also known by coeliac disease, celiac sprue, non-tropical sprue, and gluten-sensitive enteropathy - is a chronic, immune-mediated enteropathy in which dietary gluten triggers an inflammatory reaction in the small intestine of genetically predisposed individuals. Gluten is a water-insoluble protein mass that remains when the wheat dough is washed to remove starch, albumins and other water-soluble proteins. Gluten and gluten-related proteins are present in wheat, rye and barley and are used widely in food processing to give the dough the desired baking properties, add flavors and improve texture. In celiac subjects, the ingestion of gluten leads to an enteropathy with an impairment of the mucosal surface and, consequently, abnormal absorption of nutrients. CD might be considered a syndrome, because of the wide spectrum of clinical manifestations and the involvement of various human systems.

CD shows atypical features in comparison to other autoimmune disorders, including the complete recovery of the mucosal damage as well as the reversibility of its progression and chronic dynamics, with total avoidance of gluten. Alternatively, it is now established that undiagnosed CD, might have severe consequences in children as well as in adult subjects.

According to the World Gastroenterology Organization, CD may be divided into two types: classical and non-classical. However, silent type CD also exits, which is also known as an asymptomatic CD. In case of silent type, patients do not complain of any symptoms, but still, experience villous atrophy damage to their small intestine. Studies have shown that even though patients thought they had no symptoms, after going on a strict gluten-free diet, they report better health and a reduction in acid reflux, abdominal bloating and distention and flatulence.

Celiac Disease (CD) Treatment

Celiac Disease (CD) is usually treated by simply excluding foods that contain gluten from the diet. This prevents damage to the lining of the intestines (gut) and the associated symptoms, such as diarrhea and stomach pain. Symptoms generally return if the patient starts eating foods containing gluten, and it will cause long-term damage to the patient's health. Symptoms often start improving considerably within weeks of starting a gluten-free diet. However, it may take up to 2 years for the digestive system to heal completely.

Lifelong adherence to a GFD, the mainstay of treatment for CD, promotes mucosal healing, reduce serum levels of celiac antibodies, improve protein-energy deficiencies, improve bone health, and lead to increases in body fat. Non-adherent or partially adherent patients have been reported to have more fatigue, pruritus, and abdominal bloating than fully adherent patients. Similarly, the persistence of villous atrophy (VA) is less frequently reported in patients who adhere to their GFD.

Apart from avoiding gluten in the day-to-day diet, intake of certain supplements (vitamin and mineral supplements) may also be recommended, at least for the first 6 months after the diagnosis. This will ensure that the patient gets all the nutrients that are needed while the digestive system repairs itself. Taking supplements can also help correct any deficiencies, such as anemia.

In Rule Out Refractory CD I (RCDI) and RCDII, pharmacologic treatment improves symptoms and histology in only 30-40% of patients. In RCDI, symptoms often improve after treatment, while RCDII is generally less responsive to available therapies. For both RCDI and RCDII, therapeutic options reported include budesonide, systemic corticosteroids, 6-mercaptopurine, cladribine, and mesalamine. Mycophenolate mofetil and methotrexate have also been reported as therapeutic options for RCDI.

Key Findings

  • The total prevalent population of Celiac Disease in the 7 major markets was found to be 6,334,993 in 2017.

  • The total 7MM diagnosed prevalent cases of Celiac Disease in 2017 were 1,303,459 out of which the highest diagnosed prevalent cases of this disease were seen in the United States, which was 661,244.

  • The publisher has found 238,048 and 423,196 cases of males and females in the United States, in 2017.

  • It was found that in the United States the number of cases of Classical, Non-classical and Sub-clinical were 178,536, 343,847 and 138,861 respectively, in 2017.

  • In the United States the maximum number of cases of Celiac Disease were found in the age group of 19-39 with 241,354 cases in 2017, while the lowest number of cases were found in the age group >80 with 13,224 cases in 2017.

  • In the EU5 countries the total prevalent population of Celiac Disease was found to be maximum in Germany with 738,357 cases, followed by the United Kingdom with 650,676 cases in 2017. While, the least number of cases were found in Spain, i.e., 421,326 in 2017.

  • In Japan, the prevalence of CD was found to be 65,148 in 2017

Companies Mentioned

  • 9 Meters Biopharma

  • ImmunogenX

  • Provention Bio

  • Takeda/Cour Pharmaceuticals

  • Precigen ActoBio

  • Falk Pharma and Zedira

For more information about this report visit https://www.researchandmarkets.com/r/prz67c

View source version on businesswire.com: https://www.businesswire.com/news/home/20200810005429/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900